Matinas Biopharma Holdings, Inc. (MTNB) — SEC Filings
Matinas Biopharma Holdings, Inc. (MTNB) — 39 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 28 8-K, 6 10-Q, 2 DEF 14A.
View Matinas Biopharma Holdings, Inc. on SEC EDGAR
Overview
Matinas Biopharma Holdings, Inc. (MTNB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Matinas BioPharma Holdings, Inc. filed an 8-K on December 12, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral. The dominant filing sentiment for Matinas Biopharma Holdings, Inc. is neutral.
Filing Type Overview
Matinas Biopharma Holdings, Inc. (MTNB) has filed 28 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of MTNB's 37 recent filings, 3 were flagged as high-risk, 23 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$8.43M |
| Debt-to-Equity | 0.50 |
| Cash Position | $5.44M |
| Total Assets | $9.70M |
| Total Debt | $3.24M |
Key Executives
- Dr. Terry L. Horgan
- Dr. Steven M. R. Smith
- Mr. Paul E. Clancy
- Jerome Jabbour
- Dr. Paul J. Hastings
- Ms. Karen M. Smith
- Ms. Suzanne H. McInnis
- Dr. Terry H. Liang
- Dr. Raphael J. N. Mannino
- Gregory L. Weinhoff
Industry Context
Matinas BioPharma operates in the highly competitive biotechnology sector, focusing on developing novel drug delivery platforms. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Companies often rely on substantial external financing to fund operations and clinical trials, facing intense competition from both established pharmaceutical giants and emerging biotech firms.
Top Tags
corporate-governance (7) · financials (6) · executive-compensation (5) · filing (5) · board-changes (4) · 10-Q (4) · management-change (3) · board-of-directors (3) · material-agreement (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $8.43M | Decreased from $15.82M in 2024, indicating improved financial performance but still a significant loss. |
| Cash and Cash Equivalents | $5.44M | Insufficient to fund operations beyond 12 months, raising going concern doubts. |
| Accumulated Deficit | $208.88M | Reflects historical losses, indicating a long path to profitability. |
| Research and Development Expenses (9 months) | $85K | Drastically reduced from $9.06M in 2024, showing a significant cutback in R&D activities. |
| Gross Proceeds from Private Placement | $3.30M | New capital raised through preferred stock and warrants, providing short-term liquidity. |
| Warrant Reclassification | $6.10M | Shifted from liability to equity, improving the balance sheet structure. |
| Net Loss (3 months) | $1.53M | Improved from $4.28M in the prior year quarter, showing quarterly loss reduction. |
| Common Shares Outstanding | 6,406,191 | As of November 6, 2025, indicating potential for further dilution given financing needs. |
| Net Loss (H1 2025) | $6.901M | 40.2% reduction from $11.543M in H1 2024 |
| Research and Development Expenses (H1 2025) | $85K | Significant decrease from $6.817M in H1 2024 |
| General and Administrative Expenses (H1 2025) | $3.698M | 25% decrease from $4.925M in H1 2024 |
| Cash and Cash Equivalents (June 30, 2025) | $6.525M | Insufficient to fund operations beyond 12 months |
| Gross Proceeds from Preferred Stock and Warrants | $3.300M | Raised in February 2025 public offering |
| Warrants Issued | 11,262,808 | To purchase common stock alongside preferred stock |
| Accumulated Deficit (June 30, 2025) | $206.725M | Indicates historical losses |
Frequently Asked Questions
What are the latest SEC filings for Matinas Biopharma Holdings, Inc. (MTNB)?
Matinas Biopharma Holdings, Inc. has 39 recent SEC filings from Jan 2024 to Dec 2025, including 28 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MTNB filings?
Across 39 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral. The dominant sentiment is neutral.
Where can I find Matinas Biopharma Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Matinas Biopharma Holdings, Inc. (MTNB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Matinas Biopharma Holdings, Inc.?
Key financial highlights from Matinas Biopharma Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MTNB?
The investment thesis for MTNB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Matinas Biopharma Holdings, Inc.?
Key executives identified across Matinas Biopharma Holdings, Inc.'s filings include Dr. Terry L. Horgan, Dr. Steven M. R. Smith, Mr. Paul E. Clancy, Jerome Jabbour, Dr. Paul J. Hastings and 5 others.
What are the main risk factors for Matinas Biopharma Holdings, Inc. stock?
Of MTNB's 37 assessed filings, 3 were flagged high-risk, 23 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Matinas Biopharma Holdings, Inc.?
Forward guidance and predictions for Matinas Biopharma Holdings, Inc. are extracted from SEC filings as they are enriched.